The global congestive heart failure drugs market size reached US$ 8.5 Billion in 2023. Looking forward, the market is projected to reach US$ 22.6 Billion by 2032, exhibiting a growth rate (CAGR) of 11.48% during 2023-2032. The rising prevalence of obesity and cardiovascular problems, increasing geriatric population and unhealthy dietary habits represent some of the key factors driving the market.
Congestive heart failure is a medical condition that affects the pumping ability of the heart muscle. It is generally caused by hypertension, coronary artery disease, diabetes, obesity, and excessive alcohol consumption. Its symptoms include shortness of breath while lying down, weakness, fatigue, swelling in the abdomen, feet, and ankles, frequent urination at night, nausea, and difficulty in concentration. It can be prevented by maintaining a healthy weight, staying physically active, and controlling blood pressure and glycemic levels.
Besides this, it is controlled using various prescribed drugs that help prevent blood clots, expand blood vessels, strengthen the contractions of the heart, and improve heart functioning. At present, ACE inhibitors, vasodilators, digitalis glycosides, diuretics, and beta-blockers are some of the most prescribed congestive heart failure drugs. Amongst these, ACE inhibitors prevent the formation of angiotensin, which causes blood vessels to constrict, and beta blockers block the actions of certain chemicals.
Presently, the increasing global geriatric population, which is highly susceptible to diabetes and chronic cardiovascular diseases, represents one of the major factors positively influencing the market. In addition, excessive smoking and drinking of alcoholic beverages, coupled with unhealthy dietary habits of individuals, increases the risks of heart problems, which is catalyzing the demand for congestive heart failure drugs across the globe. This, coupled with the rising occurrence of heart problems due to obesity and lack of physical activity, is currently strengthening the growth of the market.
Furthermore, the increasing awareness among individuals about the benefits of early diagnosis and treatment of heart disease is creating a positive outlook for the market. Apart from this, the escalating demand for effective drugs and treatment and their approval from authorized agencies offer lucrative growth opportunities to the leading market players.
Moreover, initiatives undertaken by governments of various countries to improve healthcare infrastructure and provide optimal care to patients are contributing to the growth of the market. Additionally, the expansion of pharmacies in hospitals and residential areas and the burgeoning e-commerce industry providing easy availability of medicines at affordable rates and the facility of secured online payment methods are expected to propel the growth of the market.
2. What is the expected growth rate of the global congestive heart failure drugs market during 2024-2032?
3. What are the key factors driving the global congestive heart failure drugs market?
4. What has been the impact of COVID-19 on the global congestive heart failure drugs market?
5. What is the breakup of the global congestive heart failure drugs market based on the drug class?
6. What is the breakup of the global congestive heart failure drugs market based on the route of administration?
7. What is the breakup of the global congestive heart failure drugs market based on the distribution channel?
8. What are the key regions in the global congestive heart failure drugs market?
9. Who are the key players/companies in the global congestive heart failure drugs market?
Congestive heart failure is a medical condition that affects the pumping ability of the heart muscle. It is generally caused by hypertension, coronary artery disease, diabetes, obesity, and excessive alcohol consumption. Its symptoms include shortness of breath while lying down, weakness, fatigue, swelling in the abdomen, feet, and ankles, frequent urination at night, nausea, and difficulty in concentration. It can be prevented by maintaining a healthy weight, staying physically active, and controlling blood pressure and glycemic levels.
Besides this, it is controlled using various prescribed drugs that help prevent blood clots, expand blood vessels, strengthen the contractions of the heart, and improve heart functioning. At present, ACE inhibitors, vasodilators, digitalis glycosides, diuretics, and beta-blockers are some of the most prescribed congestive heart failure drugs. Amongst these, ACE inhibitors prevent the formation of angiotensin, which causes blood vessels to constrict, and beta blockers block the actions of certain chemicals.
Presently, the increasing global geriatric population, which is highly susceptible to diabetes and chronic cardiovascular diseases, represents one of the major factors positively influencing the market. In addition, excessive smoking and drinking of alcoholic beverages, coupled with unhealthy dietary habits of individuals, increases the risks of heart problems, which is catalyzing the demand for congestive heart failure drugs across the globe. This, coupled with the rising occurrence of heart problems due to obesity and lack of physical activity, is currently strengthening the growth of the market.
Furthermore, the increasing awareness among individuals about the benefits of early diagnosis and treatment of heart disease is creating a positive outlook for the market. Apart from this, the escalating demand for effective drugs and treatment and their approval from authorized agencies offer lucrative growth opportunities to the leading market players.
Moreover, initiatives undertaken by governments of various countries to improve healthcare infrastructure and provide optimal care to patients are contributing to the growth of the market. Additionally, the expansion of pharmacies in hospitals and residential areas and the burgeoning e-commerce industry providing easy availability of medicines at affordable rates and the facility of secured online payment methods are expected to propel the growth of the market.
Key Market Segmentation
This report provides an analysis of the key trends in each segment of the global congestive heart failure drugs market, along with forecasts at the global, regional, and country level from 2024-2032. The report has categorized the market based on drug class, route of administration, and distribution channel.Drug Class Insights:
- ACE Inhibitors
- Angiotensin 2 Receptor Blockers
- Beta Blockers
- Diuretics
- Aldosterone Antagonists
- Inotropes
- Others
Route of Administration Insights:
- Oral
- Intravenous
Distribution Channel Insights:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Regional Insights:
- North America
- United States
- Canada
- Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
- Latin America
- Brazil
- Mexico
- Others
- Middle East and Africa
Competitive Landscape
The report has also provided a comprehensive analysis of the competitive landscape in the global congestive heart failure drugs market. Detailed profiles of all major companies have also been provided. Some of the companies covered include AstraZeneca PLC, Bayer AG, Boehringer Ingelheim International GmbH (C.H. Boehringer Sohn Ag & Co. KG), Novartis AG, etc. Kindly, note that this only represents a partial list of companies, and the complete list has been provided in the report.Key Questions Answered in This Report
1. How big is the global congestive heart failure drugs market?2. What is the expected growth rate of the global congestive heart failure drugs market during 2024-2032?
3. What are the key factors driving the global congestive heart failure drugs market?
4. What has been the impact of COVID-19 on the global congestive heart failure drugs market?
5. What is the breakup of the global congestive heart failure drugs market based on the drug class?
6. What is the breakup of the global congestive heart failure drugs market based on the route of administration?
7. What is the breakup of the global congestive heart failure drugs market based on the distribution channel?
8. What are the key regions in the global congestive heart failure drugs market?
9. Who are the key players/companies in the global congestive heart failure drugs market?
Table of Contents
1 Preface3 Executive Summary11 Value Chain Analysis13 Price Analysis
2 Scope and Methodology
4 Introduction
5 Global Congestive Heart Failure Drugs Market
6 Market Breakup by Drug Class
7 Market Breakup by Route of Administration
8 Market Breakup by Distribution Channel
9 Market Breakup by Region
10 Drivers, Restraints, and Opportunities
12 Porters Five Forces Analysis
14 Competitive Landscape
List of Figures
List of Tables
Companies Mentioned
- AstraZeneca PLC
- Bayer AG
- Boehringer Ingelheim International GmbH (C.H. Boehringer Sohn Ag & Co. KG)
- Novartis AG
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 137 |
| Published | April 2024 |
| Forecast Period | 2023 - 2032 |
| Estimated Market Value ( USD | $ 8.5 Billion |
| Forecasted Market Value ( USD | $ 22.6 Billion |
| Compound Annual Growth Rate | 11.4% |
| Regions Covered | Global |
| No. of Companies Mentioned | 4 |
